Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Relative Bioavailability of Ruxolitinib XR Tablets Compared With Ruxolitinib IR Tablets Administered Orally in Healthy Participants

Next Previous
Trial Profile

Relative Bioavailability of Ruxolitinib XR Tablets Compared With Ruxolitinib IR Tablets Administered Orally in Healthy Participants

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 13 Jun 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ruxolitinib (Primary) ; Ruxolitinib (Primary)
  • Indications Acute myeloid leukaemia; Adenocarcinoma; Alopecia areata; Anaemia; Atopic dermatitis; Breast cancer; Breast disorders; Bronchiolitis obliterans; Cachexia; Chronic lymphocytic leukaemia; Chronic myeloid leukaemia; Chronic myelomonocytic leukaemia; COVID-19 pneumonia; Cytokine release syndrome; Discoid lupus erythematosus; Essential thrombocythaemia; Graft-versus-host disease; Haematological malignancies; Head and neck cancer; HER2 positive breast cancer; Hidradenitis suppurativa; HIV infections; Hodgkin's disease; Lichen planus; Multiple myeloma; Myelodysplastic syndromes; Myelofibrosis; Polycythaemia vera; Precursor cell lymphoblastic leukaemia-lymphoma; Prurigo nodularis; SARS-CoV-2 acute respiratory disease; Thalassaemia; Vitiligo; Vulvar lichen sclerosus
  • Focus Pharmacokinetics
  • Sponsors Incyte Corporation

Most Recent Events

  • 04 Jun 2024 Status changed from active, no longer recruiting to completed.
  • 09 Apr 2024 Planned End Date changed from 8 Aug 2024 to 15 May 2024.
  • 09 Apr 2024 Planned primary completion date changed from 8 Aug 2024 to 16 Apr 2024.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top